<DOC>
	<DOCNO>NCT00116701</DOCNO>
	<brief_summary>Treatment period 1 : To demonstrate switch HD subject baseline haemoglobin ( Hb ) ≥ 10 g/dL ≤ 13 g/dL either subcutaneous ( SC ) intravenous ( IV ) rHuEPO IV darbepoetin alfa result mean Hb &gt; 11 g/dL . Treatment Period 2 : To demonstrate switching subject Hb &gt; 11 g/dL ≤ 13 g/dL weekly IV darbepoetin alfa every 2 week ( Q2W ) maintain mean Hb &gt; 11 g/dL .</brief_summary>
	<brief_title>Treatment Subjects With Chronic Kidney Disease Receiving Haemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>least 18 year old Diagnosis chronic kidney disease ( CKD ) receive dialysis least 3 month prior screen Baseline Hb level great equal 10.0 g/dL less equal 13.0 g/dL Adequate iron store ( define serum ferritin great equal 100 µg/L transferrin saturation [ TSAT ] great equal 20 % ) Stable IV ( epoetin alfa beta ) SC rHuEPO ( epoetin beta ) therapy 2 3 time per week least 8 week screen ( stable define less 25 % change weekly dose change frequency route ) All subject must practice adequate contraception ( judgment investigator ) throughout trial . Received SC epoetin alfa 12 month screen Uncontrolled hypertension ( diastolic blood pressure great 100 mmHg systolic blood pressure great 180 mmHg 2 separate occasion screen ) Prior history ( within 12 week enrolment ) cardiovascular event include : acute myocardial ischemia ; hospitalization congestive heart failure ; myocardial infarction . Pregnant breastfeed woman Treatment investigational agent device within 30 day screen scheduled receive investigational agent specify protocol course study Known sensitivity product administer dose Disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Chronic Kidney Disease ( CKD )</keyword>
	<keyword>Haemoglobin ( Hb )</keyword>
	<keyword>Erthropoetin ( EPO )</keyword>
	<keyword>End Stage Renal Disease ( ESRD )</keyword>
	<keyword>Recombinant Human Erthropoetic ( rHuEPO )</keyword>
	<keyword>Anaemia</keyword>
	<keyword>Darbepoetin Alfa , Aranesp®</keyword>
	<keyword>Haemodialysis</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>